.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Nilo Azad, MD

Articles

Navigating mCRC: Treatment Options in the Third-Line Setting

November 21st 2024

Panelists discuss their preferred treatment options for patients in the third-line setting of metastatic colorectal cancer (mCRC), focusing on regorafenib, trifluridine-tipiracil plus bevacizumab, and fruquintinib, and share insights on how patient and disease-specific factors influence the selection of the most appropriate regimen for each clinical scenario.

Nuances With Defining “Refractory” mCRC in the Third-Line Setting

November 21st 2024

Panelists discuss how “refractory” metastatic colorectal cancer (mCRC) is defined in the third- vs fourth-line setting, and the treatment goals in the third-line setting, focusing on optimizing patient outcomes and managing progression after prior therapies.

Nilo Azad, MD

Articles

Navigating mCRC: Treatment Options in the Third-Line Setting

Nuances With Defining “Refractory” mCRC in the Third-Line Setting

Nilo Azad, MD